Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Chamath Palihapitiya Renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, Chamath Palihapitiya, sat down with Tucker Carlson today to talk about several topics, including AI’s...

January 24, 2025

Developments

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities...

January 23, 2025

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Developments

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and...

January 22, 2025

Developments

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx (NASDAQ:MGTX) has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD)...

January 22, 2025

Developments

Revelation launches Phase 1b study of Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) has announced the commencement of its PRIME Phase 1b clinical study evaluating escalating doses of Gemini, its intravenously administrated proprietary formulation of phosphorylated...

January 21, 2025

Developments

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non...

January 21, 2025

Developments

BioNxt moves R&D to Gen-Plus in Munich

BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective...

January 21, 2025

Developments

R&M features Izotropic in US breast cancer analysis and forecast

Izotropic (CSE:IZO; OTCQB:IZOZF; FSE:1R3) announced its inclusion in a Research and Markets (R&M) report analyzing the US breast cancer screening and diagnostic market. According to Izotropic, the R&M analysis...

January 17, 2025

Developments

Evaxion completes dosing of personalized vaccine for advanced melanoma

Evaxion Biotech (NSADAQ:EVAX) has announced the completion of dosing for 16 patients in a Phase 2 trial of its lead asset, EVX-01, a personalized cancer vaccine under development for advanced melanoma. According to...

January 16, 2025

Developments

Avicanna and Vectura forge scientific and medical affairs collaboration

Avicanna (TSX:AVCN; OTCQX:AVCNF; FSE:ONN) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma to establish a joint committee aimed at enhancing the understanding of medical cannabis...

January 16, 2025

Developments

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

OS Therapies (NYSE-A:OSTX) has announced positive data from its Phase 2b clinical trial of OST-HER2, its targeted immunotherapy candidate, in the rare, pediatric-designated indication of preventing recurrent, fully...

January 15, 2025

Developments

Peer-reviewed journal accepts Spago’s article on trial results for publication

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) announced that its article on the results of the SPANGOPIX-01 clinical trial of pegfosimer manganese (SN132D) for contrast-enhanced MRI of breast cancer has been accepted for...

January 15, 2025

Developments

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Vistagen (NASDAG:VTGN) announced positive results from its exploratory Phase 2a study of PH284, an investigational pherine nasal spray for cancer cachexia— a condition characterized by appetite loss and severe wasting...

January 15, 2025

Developments

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

Firefly Neuroscience (NASDAQ:AIFF) has announced the discovery of a novel biomarker capable of estimating the biological age of a patient’s brain through its FDA-cleared Brain Network Analytics (BNA) technology platform...

January 14, 2025

Developments

ORIC enters into clinical supply agreement with Janssen

ORIC Pharmaceuticals (NASDAQ:ORIC) has announced a supply agreement with Janssen Research & Development to evaluate ORIC-114, a brain penetrant, oral bioavailable, irreversible EGFR/HER2 inhibitor, in combination...

January 14, 2025

Developments

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...

January 14, 2025

Developments

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

Closely-held Clear Labs announced the successful completion of a $30 million series D financing round aimed at accelerating the development and adoption of its cutting-edge sequencing solutions. According to Clear Labs...

January 13, 2025

Developments

Biovica expands services with major TKa testing order

Biovica International (STO:BIOVIC-B; STO:BIOVIC.B; FRA:911) has announced the signing of a significant work order for TKa testing services, valued at 2.3 MSEK. The agreement has been made with a UK-based...

January 13, 2025

Developments

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

Closely held Arrivo BioVentures has announced promising results from its study evaluating SP-624’s novel epigenetic mechanism of action on neurological pathways. According to the company, the findings provide insights...

January 10, 2025

Developments

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Mersana Therapeutics (NASDAQ:MRSN) has announced that the FDA has granted an additional fast track designation (FTD) to its emiltatug ledadotin (XMT-1660) for the treatment of advanced or metastatic breast cancer. The...

January 10, 2025

Developments

Genenta strengthens pact with CDMO to enhance production

Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities...

January 10, 2025

Subscribe